Comparative Efficacy of Different Peptides

Why a Single Ranking Doesn't Work

Forum charts often score peptides out of 10 for muscle or recovery. We couldn't trace those numbers to any study. As of October 2026, no trial has compared two of the popular research peptides head-to-head for muscle or recovery, and most have never been tested in people for the outcome they're sold for.

A more useful comparison starts with where each compound acts. A peptide that prompts the pituitary to release growth hormone (GH) is capped by how much GH the body can make and by the feedback loops that rein it in. A peptide that binds a tissue receptor directly skips that ceiling, and loses that safety margin with it. Evidence matters just as much: a compound measured only in rats can't be fairly ranked against one tested in hundreds of patients. For background on the hormone axis most of these act on, see our explainer on the growth hormone pathway.

Pathways and Evidence at a Glance

Only tesamorelin and apitegromab are approved, each for one narrow use and neither for muscle building or fat loss. As of October 2026, WADA's 2026 Prohibited List bans every compound in the table at all times; our overview of peptide rules in sport explains the categories.

GH Secretagogues: One Hormone, Two Receptors

GHRPs such as ipamorelin and GHRP-6 act on the ghrelin receptor. GHRH analogs such as CJC-1295 mimic the hypothalamic signal that tells the pituitary to release GH. Both routes end in more of the body's own GH, followed by more insulin-like growth factor 1 (IGF-1), mostly made in the liver. That shared endpoint is why users commonly pair one of each, although no controlled trial has tested the popular Mod GRF 1-29 plus ipamorelin combination.

Most of the human data measure hormone levels, not results. In two 2006 trials in healthy adults, a single injection of CJC-1295 raised GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days. Neither trial measured muscle or fat. Ipamorelin's only efficacy trial, a Phase 2 study after abdominal surgery, missed its primary endpoint, per an October 2024 FDA advisory review: median time to a first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, not a significant difference. That's why the site rates ipamorelin's evidence as moderate.

Where this pathway has been tested for body composition, the effects are modest. MK-677, an oral non-peptide drug acting on the same ghrelin receptor, added about 1.1 kg of fat-free mass over a year in 65 healthy adults aged 60-81, against a 0.5 kg loss on placebo. Strength didn't change and fat mass didn't differ from placebo, while fasting glucose rose. Tesamorelin, a GHRH analog prescribed for excess abdominal fat in HIV, cut visceral fat by 15.2% over 26 weeks in a 412-person trial, versus a 5.0% rise on placebo. Yet its FDA label says it isn't indicated for weight loss because its effect on body weight is neutral.

Forum tables often put hexarelin first for "potency", but we couldn't find a study comparing these compounds at the doses users describe. Hexarelin does show a known limit of the class: in 12 healthy older adults injecting twice daily for 16 weeks, the GH response fell by about 45%, then recovered within four weeks of stopping. Our page on peptide cycling protocols covers how users respond to that.

IGF-1 LR3: Skipping the Pituitary

IGF-1 LR3 is an engineered IGF-1 that binds the IGF-1 receptor in muscle and other tissues directly, so it doesn't depend on the pituitary. Its key design change is that it barely binds the IGF-binding proteins that normally carry IGF-1 in the blood and buffer its effects. In rat and cell studies, that made it more potent than native IGF-1.

The often-quoted "20-30 hour half-life" has no measured source that we could find, and the rat data point the other way. In a 1993 study, non-pregnant rats cleared LR3 from the blood about 11 times faster than native IGF-1 (9.84 vs. 0.90 ml/min per kg). No human pharmacokinetic study exists, and as of October 2026 there are no human trials of any kind, so the site rates its evidence as preliminary.

Direct receptor action also explains the main risk. IGF-1 has insulin-like effects, and hypoglycemia is the acute problem users report most often. FDA says it has found no human exposure data for PEG-MGF, another IGF-family peptide on vendor lists.

Repair Peptides: Consistent in Rats, Untested in People

BPC-157 and TB-500 are thought to act locally on damaged tissue rather than through hormones. In rodent studies, BPC-157 has been linked to new blood-vessel growth (angiogenesis) and lower inflammatory signaling. TB-500 is a seven-amino-acid fragment (LKKTETQ) of the much larger protein thymosin beta-4. The mechanism is plausible, but the human evidence doesn't support the top scores these two get on forum charts.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, 35 of them preclinical. The one clinical study was an uncontrolled retrospective series in which 7 of 12 patients with chronic knee pain reported relief lasting over six months. The reviewers found no clinical safety data. As of October 2026, no controlled human trial of BPC-157 has published results, so the site rates its evidence as emerging. For the TB-500 fragment, FDA's compounding safety page says the agency hasn't identified any human exposure data, and trials of full thymosin beta-4 don't carry over, so the site rates it as preliminary.

So a "9/10 safety" score has nothing behind it: no reported harm in rats over a few weeks isn't safety in people over months. Our article on long-term effects of peptides covers what's known about longer use. User reports are split between clear improvement and no change at all; natural healing and inconsistent gray-market products could explain part of that gap.

GH Fragments: A Mechanism That Didn't Translate

hGH fragment 176-191 and AOD-9604 (the 177-191 stretch of growth hormone with an added tyrosine) were developed as the fat-burning piece of growth hormone, meant to work without GH's other effects. FDA's December 2024 review notes that in cell studies AOD-9604 didn't bind the GH receptor, and it describes the molecular target as unknown.

The idea didn't hold up in human trials. In the OPTIONS Phase 2b trial, 536 adults with obesity took oral AOD-9604 (three doses between 0.25 and 1 mg daily) or placebo for 24 weeks. Weight loss at 12 weeks, the primary endpoint, wasn't significantly different from placebo, and the developer ended work on it for obesity in February 2007. FDA found that most trials it reviewed showed no weight benefit over placebo, and it found no human data for the subcutaneous route users rely on. A "High" rating for direct fat loss doesn't fit that record.

Myostatin Blockers: From Discontinued to Approved

Myostatin limits muscle growth, so blocking it works from a different angle than raising GH. These drugs are antibodies and large proteins rather than short peptides.

ACE-031, a decoy receptor for myostatin and related proteins, isn't a current option. Its Phase 2 trial in boys with Duchenne muscular dystrophy was stopped in 2011 after minor bleeding and dilated skin blood vessels, and the developers discontinued it in May 2013.

As of October 2026, the first approved myostatin-targeted drug is apitegromab (Isembyld), an antibody FDA approved in September 2026 for spinal muscular atrophy in patients already on an SMN2-targeted treatment. In its 52-week trial, children aged 2-12 on the approved dose were more than twice as likely as those on placebo to show meaningful motor improvement (34.2% vs. 13.5%); the label warns of fracture risk. It's a prescription infusion for a rare disease; research-use vials sold online aren't equivalent.

What We Still Don't Know

• Whether hormone changes become results. Secretagogue trials show GH and IGF-1 rising, but none has tested strength in young, trained adults.
• BPC-157 in human tendons. A University of Arkansas Phase 1 trial (NCT07803250) plans to randomize 30 people after rotator cuff surgery, with a listed start of January 2027 as of October 2026. It would be the first controlled test.
• Myostatin blockade beyond rare disease. Developers hope the class can preserve muscle during weight loss, according to a September 2026 Nature Reviews Drug Discovery report, but apitegromab is approved only for SMA.